- Home
- FTV vs DGX Comparison
FTV vs DGX Comparison
Compare FTV & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTV
- DGX
- Stock Information
- Founded
- FTV 2015
- DGX 1967
- Country
- FTV United States
- DGX United States
- Employees
- FTV N/A
- DGX N/A
- Industry
- FTV Industrial Machinery/Components
- DGX Medical Specialities
- Sector
- FTV Industrials
- DGX Health Care
- Exchange
- FTV Nasdaq
- DGX Nasdaq
- Market Cap
- FTV 16.3B
- DGX 20.5B
- IPO Year
- FTV N/A
- DGX 1996
- Fundamental
- Price
- FTV $50.55
- DGX $185.24
- Analyst Decision
- FTV Hold
- DGX Buy
- Analyst Count
- FTV 13
- DGX 15
- Target Price
- FTV $58.42
- DGX $194.07
- AVG Volume (30 Days)
- FTV 3.4M
- DGX 1.1M
- Earning Date
- FTV 10-29-2025
- DGX 10-21-2025
- Dividend Yield
- FTV 0.48%
- DGX 1.73%
- EPS Growth
- FTV N/A
- DGX 14.49
- EPS
- FTV 1.75
- DGX 8.51
- Revenue
- FTV $6,260,300,000.00
- DGX $10,850,000,000.00
- Revenue This Year
- FTV N/A
- DGX $12.37
- Revenue Next Year
- FTV $3.07
- DGX $3.51
- P/E Ratio
- FTV $28.74
- DGX $21.77
- Revenue Growth
- FTV 36.34
- DGX 13.74
- 52 Week Low
- FTV $46.34
- DGX $148.70
- 52 Week High
- FTV $83.32
- DGX $197.55
- Technical
- Relative Strength Index (RSI)
- FTV 51.12
- DGX 55.04
- Support Level
- FTV $49.99
- DGX $184.50
- Resistance Level
- FTV $52.66
- DGX $189.26
- Average True Range (ATR)
- FTV 1.03
- DGX 4.26
- MACD
- FTV -0.04
- DGX 0.84
- Stochastic Oscillator
- FTV 40.53
- DGX 65.24
About FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.